

# Rieke E Alten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4021508/publications.pdf>

Version: 2024-02-01

120  
papers

8,419  
citations

66234

42  
h-index

46693

89  
g-index

136  
all docs

136  
docs citations

136  
times ranked

8438  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2008, 371, 987-997.	6.3	1,269
2	Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4lg. <i>New England Journal of Medicine</i> , 2003, 349, 1907-1915.	13.9	973
3	Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. <i>Lancet, The</i> , 2013, 381, 1541-1550.	6.3	568
4	Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4lg and LEA29Y eighty-five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002, 46, 1470-1479.	6.7	354
5	Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2008, 371, 205-214.	6.3	340
6	Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. <i>Arthritis Research and Therapy</i> , 2009, 11, R6.	1.6	297
7	Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1839-1848.	0.5	289
8	Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 844-850.	0.5	168
9	Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 45-51.	0.5	165
10	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 204-210.	0.5	160
11	The human anti-IL-1 <sup>β</sup> monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2008, 10, R67.	1.6	150
12	Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. <i>Arthritis Care and Research</i> , 2012, 64, 206-214.	1.5	144
13	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1855-1860.	0.5	131
14	Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 153.	0.8	128
15	'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. <i>Rheumatology</i> , 2012, 51, 69-76.	0.9	121
16	Developing a Standardized Definition for Disease "Flare" in Rheumatoid Arthritis (OMERACT 9 Special) <i>TJ ETQ</i> 0.0 0 rgBT / Overlock	1.0	108
17	Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1275-1280.	0.5	91
18	Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 935-947.	1.5	89

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 364-367.	0.5	85
20	Hypothalamus-Pituitary-Adrenal Axis Function in Patients with Rheumatoid Arthritis Treated with Nighttime-Release Prednisone. <i>Journal of Rheumatology</i> , 2010, 37, 2025-2031.	1.0	85
21	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018, 32, 397-404.	2.2	82
22	Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1637-1644.	0.5	73
23	Clinical trial development for biosimilars. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S2-S8.	1.6	70
24	Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. <i>Annals of Medicine</i> , 2013, 45, 357-363.	1.5	65
25	Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. <i>Journal of Rheumatology</i> , 2014, 41, 799-809.	1.0	65
26	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1751-1761.	2.9	65
27	Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2217-2228.	0.8	64
28	Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. <i>Journal of Rheumatology</i> , 2007, 34, 1401-14.	1.0	64
29	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1942-1949.	0.5	59
30	Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 231.	0.8	58
31	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	4.9	58
32	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016, 2, e000302.	1.8	57
33	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. <i>RMD Open</i> , 2016, 2, e000225.	1.8	54
34	Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. <i>Arthritis Research and Therapy</i> , 2018, 20, 1.	1.6	53
35	Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. <i>RMD Open</i> , 2016, 2, e000308.	1.8	50
36	Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment. <i>Arthritis and Rheumatology</i> , 2014, 66, 1987-1997.	2.9	48

#	ARTICLE	IF	CITATIONS
37	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	1.5	48
38	Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 399-407.	0.5	48
39	Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1287-1294.	0.5	47
40	Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2007, 34, 510-5.	1.0	47
41	A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 155.	1.6	45
42	Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 14.	0.8	44
43	A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 178.	1.6	44
44	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. <i>Journal of Rheumatology</i> , 2015, 42, 2185-2189.	1.0	40
45	Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 754-760.	0.5	38
46	Dose optimization of infliximab in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 5-18.	0.9	36
47	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 176.	0.8	36
48	Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. <i>RMD Open</i> , 2017, 3, e000345.	1.8	35
49	FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. <i>Arthritis Research and Therapy</i> , 2019, 21, 281.	1.6	34
50	Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial. <i>Journal of Rheumatology</i> , 2014, 41, 629-639.	1.0	33
51	German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. <i>Rheumatology International</i> , 2014, 34, 1-9.	1.5	33
52	Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge. <i>Arthritis Care and Research</i> , 2017, 69, 58-66.	1.5	30
53	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. <i>Journal of Rheumatology</i> , 2021, 48, 1230-1238.	1.0	29
54	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. <i>Journal of Rheumatology</i> , 2018, 45, 1085-1092.	1.0	28

#	ARTICLE	IF	CITATIONS
55	Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 553-62.	0.4	28
56	Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. <i>RMD Open</i> , 2021, 7, e001681.	1.8	28
57	Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial. <i>Journal of Rheumatology</i> , 2014, 41, 2034-2040.	1.0	27
58	Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 2655-2665.	1.0	27
59	OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. <i>Journal of Rheumatology</i> , 2014, 41, 569-573.	1.0	26
60	The importance of patient participation in measuring rheumatoid arthritis flares. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1107-1109.	0.5	25
61	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. <i>Journal of Rheumatology</i> , 2017, 44, 1536-1543.	1.0	25
62	New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis – Implications from the prospective multicenter VADERA II study. <i>PLoS ONE</i> , 2019, 14, e0217412.	1.1	25
63	Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 489-99.	0.4	22
64	Differential surface expression of HLA-DRB1 and HLA-DRB4 among peripheral blood cells of DR4 positive individuals. <i>Human Immunology</i> , 1999, 60, 1-9.	1.2	21
65	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	1.0	21
66	Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. <i>Clinical Rheumatology</i> , 2019, 38, 1413-1424.	1.0	21
67	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018, 4, e000615.	1.8	20
68	Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017. <i>Rheumatology International</i> , 2020, 40, 2005-2012.	1.5	20
69	Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. <i>RMD Open</i> , 2020, 6, e001240.	1.8	20
70	Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 123-133.	1.3	19
71	Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000134.	1.8	19
72	The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. <i>Joint Bone Spine</i> , 2017, 84, 571-576.	0.8	19

#	ARTICLE	IF	CITATIONS
73	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	0.7	19
74	Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. <i>Clinical Rheumatology</i> , 2019, 38, 1615-1626.	1.0	19
75	Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. <i>Acta Neuropathologica</i> , 2021, 141, 917-927.	3.9	19
76	Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. <i>RMD Open</i> , 2017, 3, e000538.	1.8	18
77	Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. <i>RMD Open</i> , 2019, 5, e000876.	1.8	18
78	Tocilizumab: A Novel Humanized Anti-Interleukin 6 Receptor Antibody for the Treatment of Patients with Rheumatoid Arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2011, 3, 133-149.	1.2	17
79	Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib. <i>Arthritis Research and Therapy</i> , 2020, 22, 243.	1.6	17
80	Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. <i>RMD Open</i> , 2020, 6, e000987.	1.8	17
81	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , 2021, 13, 1868078.	2.6	17
82	Hypothalamic-Pituitary-Adrenal Axis Function in Patients with Rheumatoid Arthritis Treated with Different Glucocorticoid Approaches. <i>NeuroImmunoModulation</i> , 2015, 22, 83-88.	0.9	15
83	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. <i>RMD Open</i> , 2016, 2, e000228.	1.8	15
84	Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. <i>RMD Open</i> , 2022, 8, e001994.	1.8	15
85	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. <i>Journal of Rheumatology</i> , 2019, 46, 1409-1414.	1.0	14
86	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 85-100.	1.3	14
87	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	1.6	13
88	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	1.6	13
89	Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e767-e777.	2.2	13
90	Development and Validation of a New Disease Activity Score in 28 Joints-Based Treatment Response Criterion for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 1608-1616.	1.5	12

#	ARTICLE	IF	CITATIONS
91	Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e446-e455.	0.5	12
92	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 57-69.	1.1	11
93	Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1904-1910.	1.0	11
94	Physical and Emotional Burden of Rheumatoid Arthritis: Data from RA Matters, a Web-Based Survey of Patients and Healthcare Professionals. <i>Rheumatology and Therapy</i> , 2019, 6, 587-597.	1.1	10
95	Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54â€“78 Data From a Randomized, Double-Blind, Phase III Trial. <i>BioDrugs</i> , 2020, 34, 197-207.	2.2	10
96	Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26â€“52, including a treatment switch from reference ADL to PF-06410293. <i>RMD Open</i> , 2021, 7, e001578.	1.8	10
97	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	1.3	10
98	An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1734-1739.	1.0	9
99	Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status. <i>Journal of Rheumatology</i> , 2019, 46, 460-466.	1.0	9
100	Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52â€“92 data from a randomized, double-blind, phase 3 trial. <i>Arthritis Research and Therapy</i> , 2021, 23, 248.	1.6	9
101	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Rheumatology and Therapy</i> , 2022, 9, 781-802.	1.1	9
102	Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1514-1525.	0.9	8
103	Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). <i>Rheumatology</i> , 2021, 60, 5318-5328.	0.9	8
104	New concepts to reduce glucocorticoid toxicity. <i>Joint Bone Spine</i> , 2019, 86, 715-723.	0.8	7
105	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	1.3	7
106	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	1.6	7
107	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	7
108	Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. <i>Clinical Drug Investigation</i> , 2022, 42, 477-489.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. <i>Journal of Rheumatology</i> , 2019, 46, 1406-1408.	1.0	6
110	Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2007-2014.	0.8	5
111	Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study. <i>Wiener Medizinische Wochenschrift</i> , 2020, 170, 132-140.	0.5	4
112	2021 ACR guideline reflects changes in RA treatment. <i>Nature Reviews Rheumatology</i> , 2021, 17, 513-514.	3.5	4
113	Physical and Emotional Burden of Rheumatoid Arthritis in Saudi Arabia: An Exploratory Cross-Sectional Study. <i>Open Access Rheumatology: Research and Reviews</i> , 2020, Volume 12, 337-345.	0.8	4
114	Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. <i>Clinical Rheumatology</i> , 2019, 38, 3049-3059.	1.0	3
115	Systematic analysis of injection-site pain and reactions caused by subcutaneous administration of the adalimumab biosimilar FKB327 versus the adalimumab reference product via different delivery methods. <i>GaBI Journal</i> , 2020, 9, 108-115.	0.4	3
116	AB0361â€¦ASCORE, A 2-YEAR, OBSERVATIONAL, PROSPECTIVE MULTICENTRE STUDY OF SUBCUTANEOUS ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE: 1-YEAR INTERIM ANALYSIS. , 2019, , .		1
117	Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 935-936.	0.4	1
118	Dr. Alten replies. <i>Journal of Rheumatology</i> , 2011, 38, 1519.2-1519.	1.0	0
119	Effets de lâ€™indice de masse corporelle sur la r�ponse clinique � abatacept en traitement biologique de premi�re ligne de la polyarthrite rhumato�de: r�sultats � 6 mois de lâ€™�tude observationnelle prospective de deux ans ACTION. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 359-364.	0.0	0
120	Nouveaux concepts destin�s � r�duire la toxicit� des glucocortico�des. <i>Revue Du Rhumatisme (Edition) Tj</i> 0.0	0.0	0